Cancer Family
Secondary Malignant Neoplasm
CI-CAN-00000346SMNExplore in graph →
4,275 active trials56 approved drugs532 evidence items
- NCIt
- C4968
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000346SMNExplore in graph →
Clinical trials
14,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,961)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06901856 | Endoscopic Resection for Small Rectal Neuroendocrine Tumors | not yet recruiting | N/A | 120 | Guangdong Provincial People's HospitalOTHER | 0 | Mar 30, 2025 | clinicaltrials |
| NCT06900478 | Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC | not yet recruiting | Phase 2 | 25 | Hua LiOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06895369 |
| The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC |
| not yet recruiting |
| Phase 2 |
| 30 |
| Sir Run Run Shaw HospitalOTHER |
| 1 |
| Mar 26, 2025 |
| clinicaltrials |
| NCT06896396 | Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 60 | Zhiyong HuangOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06894524 | Retrospective Clinical Validation of HepatoPredict | not yet recruiting | — | 200 | OphiomicsINDUSTRY | 0 | Mar 25, 2025 | clinicaltrials |
| NCT05835804 | Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers(NIVOCHIMLOC) | not yet recruiting | Phase 2 | 39 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06888037 | Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer | not yet recruiting | Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06884982 | An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib | not yet recruiting | Phase 2 | 30 | Northern Jiangsu People's HospitalOTHER | 0 | Mar 19, 2025 | clinicaltrials |
| NCT06869174 | Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary | not yet recruiting | Phase 2 | 50 | Zhiguo Luo, MD, PhDOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06871527 | Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 44 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06871930 | Characteristic and Survival Outcomes in Hepatocellular Carcinoma Patients: on Top of Viral Hepatitis Versus Combined Viral and Metabolic-Associated Steatotic Liver Disease | not yet recruiting | — | 150 | Assiut UniversityOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT06872606 | Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer(SCRIPBOT) | not yet recruiting | Phase 2 | 33 | Sir Run Run Shaw HospitalOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06743386 | Pilot Study of EUS-Guided Radiofrequency and FOLFIRINOX in Advanced Pancreatic Cancer (RadioFAP )(RadioFAP) | not yet recruiting | N/A | 30 | French Society of Digestive EndoscopyOTHER | 0 | Mar 11, 2025 | clinicaltrials |
| NCT06861777 | Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC | not yet recruiting | Phase 2 / Phase 3 | 474 | YIN LIOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT05195294 | Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC | not yet recruiting | Phase 2 | 55 | Lion TCR Pte. Ltd.INDUSTRY | 0 | Mar 10, 2025 | clinicaltrials |
| NCT06867432 | Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 10, 2025 | clinicaltrials |
| NCT06868017 | Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles | not yet recruiting | Phase 4 | 208 | The First Hospital of Jilin UniversityOTHER | 0 | Mar 10, 2025 | clinicaltrials |
| NCT06861036 | Heterogeneity of Oral Squamous Cell Carcinoma Analysis by Single Cell RNA Sequencing(HOASIS) | not yet recruiting | N/A | 50 | Centre Leon BerardOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT06861218 | Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases | not yet recruiting | Phase 2 | 42 | Zhejiang Cancer HospitalOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT06858410 | Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma | not yet recruiting | Phase 3 | 36 | Guangdong Association of Clinical TrialsOTHER | 0 | Mar 5, 2025 | clinicaltrials |
| NCT06860217 | Robotic Nipple Sparing Mastectomy with Immediate Reconstruction | not yet recruiting | N/A | 24 | European Institute of OncologyOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT06852456 | QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 28, 2025 | clinicaltrials |
| NCT06848920 | Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma | not yet recruiting | Phase 2 | 20 | Zhejiang UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06849492 | HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer(SHIFT-001) | not yet recruiting | Phase 2 | 120 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06841185 | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 3 | 656 | Shanghai Henlius BiotechINDUSTRY | 0 | Feb 24, 2025 | clinicaltrials |
| NCT06836518 | Sialic Acid in Hepatocellular Carcinoma | not yet recruiting | — | 100 | Sohag UniversityOTHER | 0 | Feb 20, 2025 | clinicaltrials |
| NCT06836778 | Comparative Study of Carvedilol Monotherapy Versus Combination Therapy With Endoscopic Variceal Ligation (EVL) for Primary Prophylaxis of Variceal Bleeding in Patients With Hepatocellular Carcinoma With High-Risk Esophageal Varices | not yet recruiting | N/A | 100 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT05821686 | Efficacy of Interleukin-2 in Triple Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 10 | Nova Scotia Health AuthorityOTHER | 0 | Feb 12, 2025 | clinicaltrials |
| NCT06818955 | Orlistat Overcoming Third-generation EGFR-TKI Resistance(OOTER) | not yet recruiting | Phase 2 | 36 | Ping PengOTHER | 0 | Feb 12, 2025 | clinicaltrials |
| NCT06822985 | QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma(QL1706) | not yet recruiting | Phase 1 | 21 | Wan-Guang ZhangOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06823050 | A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC | not yet recruiting | — | 59 | Xuhua DuanOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06789796 | a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy. | not yet recruiting | Phase 3 | 636 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 11, 2025 | clinicaltrials |
| NCT06820762 | Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study | not yet recruiting | Phase 2 | 40 | The Second Affiliated Hospital of Dalian Medical UniversityOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06677242 | Serous Endometrial Intraepithelial Carcinoma (SEIC): Prospective Registration Study(SEIC) | not yet recruiting | — | 100 | Erasmus Medical CenterOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06750861 | QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC | not yet recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06814067 | Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06815705 | Reconstruction of Cervical Lymphatic System During Head and Neck Squamous Cell Carcinoma Surgery | not yet recruiting | N/A | 23 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06807112 | The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma | not yet recruiting | — | 39 | Charles University, Czech RepublicOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06805864 | Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma(BROTHER) | not yet recruiting | Phase 2 | 45 | Gunma UniversityOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06798194 | Fusing Ultrasound and Magnetic Resonance Imaging to Intelligently Plan Highly Conformal Ablation Thermal Field for Hepatocellular Carcinoma | not yet recruiting | — | 300 | Chinese PLA General HospitalOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06795503 | Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients | not yet recruiting | Phase 3 | 1,462 | Fudan UniversityOTHER | 0 | Jan 28, 2025 | clinicaltrials |
| NCT06793228 | Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia | not yet recruiting | Phase 2 | 250 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06792097 | Ga-68 Dolacga PET Scan in HCC Under RFA(HCC; RFA) | not yet recruiting | — | 10 | National Taiwan University HospitalOTHER | 0 | Jan 24, 2025 | clinicaltrials |
| NCT06786312 | A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer | not yet recruiting | Phase 2 | 34 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06784206 | Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06773377 | Study of the Prognostic Impact of CD44 on Renal Cell Carcinoma | not yet recruiting | — | 77 | Assiut UniversityOTHER | 0 | Jan 14, 2025 | clinicaltrials |
| NCT06774768 | Use of Machine-learning Algorithms, Biomarkers and Measures of Quality of Life to Personalize Medical Management of Liver and Heart Transplant Recipients(DARE) | not yet recruiting | — | 1,000 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06766591 | Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs | not yet recruiting | N/A | 36 | Jiangsu Province Nanjing Brain HospitalOTHER | 0 | Jan 9, 2025 | clinicaltrials |
| NCT06764368 | Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors | not yet recruiting | Phase 2 | 39 | Beijing Chest HospitalOTHER | 0 | Jan 8, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 30, 2025source: clinicaltrials